Therapy with GLP-1 RA reduced ferroptosis and systemic/myocardial levels of NLRP-3, MyD88, IL-1, IL-6 and IL-18, supporting their use in cancer patients treated with anthracyclines and ICIs. The gene discussed is MYD88; the disease is cancer.